1 min readProxeon Joins Research Consortium
According to the announcement, the project will focus on development of new proteomics technologies to provide unique insights and a deeper understanding of the human proteome and its role in disease. There will be specific focus on functional proteomics and mass spectrometry.
PROSPECTS collaborators come from leading proteomics laboratories and companies in the complementary fields of proteomics, structural and cell biology, cell imaging, bioinformatics and data-mining, and computational modelling of proteomic data. The goal is to annotate quantitatively the human proteome with respect to protein localization and dynamics.
All data produced during the project will be available to the scientific community via annotated online public databases Proxeon’s participation will be led by the company’s Chief Scientific Officer, Dr. Ole Vorm, and focus towards increasing the sensitivity and dynamic range of nanoscale liquid chromatography (nano LC) by one to two orders of magnitude.
Dr. Vorm, elaborated, “We have committed to turning two of our research discoveries into novel instrument solutions that could greatly advance proteomics research. Our involvement in PROSPECTS enables us to work even more closely with leading proteomics groups. We are confident that working within such a strong team of innovative scientists presents the perfect opportunity for developing breakthrough technology.”
PROSPECT is headed by proteomics researcher, Dr. Matthias Mann. Other partners in the consortium are Max Planck Institute of Biochemistry and ThermoFisher in Germany; Swiss Federal Institute of Technology; University of Cambridge and University of Dundee, UK; University of Southern Denmark; Center for Genomic Regulation, Spain, The Royal Institute of Technology, Sweden and the Hebrew University, Israel. The consortium is co-funded by the European Commission with 12 Million Euros for five years (2008 – 2013) within the Research Framework Programme 7.